SAN FRANCISCO—Cumulative mortality from prostate cancer 15 years after radical prostatectomy is six times lower than death from other causes, according to study findings presented here at the Genitourinary Cancers Symposium.
SAN FRANCISCO—Skeletal-related events (SREs) in patients with metastatic hormone-refractory prostate cancer (mHRPC) are mostly due to bony metastatic disease and not decreased bone mineral density (BMD), according to British researchers.
SAN FRANCISCO—Radical prostatectomy (RP) is associated with improved overall survival compared with radiation therapy in men with clinically localized prostate cancer, data suggest.
SAN FRANCISCO—Alcohol consumption may be associated with an increased risk of prostate cancer in African-American men, according to researchers.
SAN FRANCISCO—A new urine test based on a highly specific gene-fusion biomarker may accurately predict the presence of clinically significant prostate cancers at biopsy and radical prostatectomy, according to findings presented here at the Genitourinary Cancers Symposium.
SAN FRANCISCO—The prostate cancer gene 3 (PCA3) molecular urine test is more accurate than the PSA test in predicting outcomes of repeat biopsies, new findings confirm.
SAN FRANCISCO—Even 30 years after radical prostatectomy for prostate cancer, prostate cancer-specific and metastasis-free survival are excellent, researchers have concluded.
SAN FRANCISCO—Cabazitaxel, a novel taxane, prolongs survival better than mitoxantrone in patients with metastatic castration-resistant prostate cancer (mCRPC) and who had failed previous treatment with docetaxel, according to new findings from a phase 3 trial presented here today at the Genituourinary Cancers Symposium.
Please login or register first to view this content.
